FDA, EMA Lay Out Incretin Mimetic Safety Analysis In NEJM
This article was originally published in The Pink Sheet Daily
Executive Summary
Editorial details the breadth of data that U.S. and European regulators examined in concluding that available data are “inconsistent” with assertions that a causal association exists between incretin-based diabetes drugs and pancreatic adverse events.